Expression of the chemokine antagonist vMIP II using a non-viral vector can prolong corneal allograft survival

Transplantation

Volumn 85, Issue 11, 2008, Pages 1640-1647

  Pillai, Radhakrishna G ^a   Beutelspacher, Sven C ^a,b,c   Larkin, D Frank P ^b   George, Andrew J T ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Chemokine; Chemokine antagonist; Corneal transplantation; Gene therapy; Keratoplasty

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; LIPOSOME; TRANSFERRIN; UNCLASSIFIED DRUG; VIRUS MACROPHAGE INFLAMMATORY PROTEIN II; VIRUS VECTOR; BETA CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR; RNA; VMIP II; VMIP-II;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA CELL; CORNEA ENDOTHELIUM; CORNEA TRANSPLANTATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; GRAFT SURVIVAL; LEUKOCYTE; LEUKOCYTE MIGRATION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; FOLLOW UP; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOHISTOCHEMISTRY; METHODOLOGY; PHYSIOLOGY; PROGNOSIS; TIME; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CHEMOKINES; CHEMOKINES, CC; CORNEAL TRANSPLANTATION; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; PLASMIDS; PROGNOSIS; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 47049101220     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318172813f     Document Type: Article

References (59)

1. Darlington JK, Adrean SD, Schwab IR. Trends of penetrating kerato-plasty in the United States from 1980 to 2004. Ophthalmology 2006; 113: 2171.
2. Williams KA, Esterman AJ, BartlettC,et al. How effectiveispenetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation 2006; 81: 896.
3. Williams KA, Muehlberg SM, Lewis RF, et al. How successful is corneal transplantation? A report from the Australian Corneal Graft Register. Eye 1995; 9: 219.
4. Hill JC. Systemic cyclosporine in high-risk keratoplasty: Long-term results. Eye 1995; 9: 422.
5. Birnbaum F, Bohringer D, Sokolovska Y, et al. Immunosuppression with cyclosporineAand mycophenolate mofetil after penetrating high-risk keratoplasty: A retrospective study. Transplantation 2005; 79: 964.
6. Coster DJ, Williams KA. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation. Am J Ophthalmol 2005; 140: 1112.
7. Williams KA, Coster DJ. The immunobiology of corneal transplantation. Transplantation 2007; 84: 806.
8. George AJ, Larkin DF. Corneal transplantation: The forgotten graft. Am J Transplant 2004; 4: 678.
9. Pleyer U, Bertelmann E, Rieck P, et al. Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4. Graefes Arch Clin Exp Ophthalmol 2000; 238: 531.
10. Klebe S, Sykes PJ, Coster DJ, et al. Prolongation of sheep corneal allo-graft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 2001; 71: 1214.
11. Klebe S, Coster DJ, Sykes PJ, et al. Prolongation of sheep corneal allo- graft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium. J Immunol 2005; 175: 2219.
12. Rayner SA, Larkin DF, George AJ. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest Ophthalmol Vis Sci 2001; 42: 1568.
13. Murthy RC, McFarland TJ, Yoken J, et al. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophthalmol Vis Sci 2003; 44: 1837.
14. Comer RM, King WJ, Ardjomand N, et al. Effect of administration of CTLA4-IgasproteinorcDNAoncorneal allograft survival.Invest Oph-thalmol Vis Sci 2002; 43: 1095.
15. Beutelspacher SC, Pillai R, Watson MP, et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of al-lograft survival by over-expression. Eur J Immunol 2006; 36: 690.
16. Tan PH, King WJ, Chen D, et al. Transferrin receptor-mediated gene transfer to the corneal endothelium. Transplantation 2001; 71: 552.
17. Larkin DF, Oral HB, Ring CJ, et al. Adenovirus-mediated gene delivery to the corneal endothelium. Transplantation 1996; 61: 363.
18. Tan PH, Xue SA, Manunta M, et al. Effect of vectors on human endo-thelial cell signal transduction: Implications for cardiovascular gene therapy. Arterioscler Thromb Vasc Biol 2006; 26: 462.
19. Tan PH, Beutelspacher SC, Xue SA, et al. Modulation of human dendritic-cell function following transduction with viral vectors: Implications for gene therapy. Blood 2005; 105: 3824.
20. Hudde T, Rayner SA, Comer RM, et al. Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endo-thelium. Gene Ther 1999; 6: 939.
21. Tan PH, Manunta M, Ardjomand N, et al. Antibody targeted gene transfer to endothelium. J Gene Med 2003; 5: 311.
22. Garrood T, Lee L,PitzalisC. Molecular mechanisms ofcell recruitment to inflammatory sites: General and tissue-specific pathways. Rheumatology (Oxford) 2006; 45: 250.
23. Campbell JJ, Hedrick J, Zlotnik A, et al. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 1998; 279: 381.
24. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19: 568.
25. Luster AD. Chemokines - Chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436.
26. Allen SJ, Crown SE, Handel TM. Chemokine: Receptor structure, interactions and antagonism. Annu Rev Immunol 2007; 25: 787.
27. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angio-genesis. J Leukoc Biol 2000; 68: 1.
28. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677.
29. Kledal TN, Rosenkilde MM, Coulin F, et al. A broad-spectrum chemo-kine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997; 277: 1656.
30. Luttichau HR, Lewis IC, Gerstoft J, et al. The herpesvirus 8-encoded chemokine vMIP-II, but not the poxvirus-encoded chemokine MC148, inhibits the CCR10 receptor. Eur J Immunol 2001; 31: 1217.
31. Luttichau HR, Stine J, Boesen TP, et al. A highly selective CC chemo-kine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum. J Exp Med 2000; 191: 171.
32. Nakano K, Isegawa Y, Zou P, et al. Kaposi's sarcoma-associated her-pesvirus (KSHV)-encoded vMIP-I and vMIP-II induce signal trans-duction and chemotaxis in monocytic cells. Arch Virol 2003; 148: 871.
33. DeBruyne LA, Li K, Bishop DK, et al. Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity. Gene Ther 2000; 7: 575.
34. Sozzani S, Luini W, Bianchi G, et al. The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood 1998; 92: 4036.
35. Hazlett LD. Corneal response to Pseudomonas aeruginosa infection. Prog Retin Eye Res 2004; 23: 1.
36. Lundberg P, Cantin E. A potential role for CXCR3 chemokines in the response to ocular HSV infection. Curr Eye Res 2003; 26: 137.
37. Nour M, Chodosh J. Chemokine signaling pathways in corneal fibro-blasts. Ocul Surf 2005; 3(4 suppl): S149.
38. Spandau UH, Toksoy A, Verhaart S, et al. High expression of chemo-kines Gro-alpha (CXCL-1), IL-8 (CXCL-8), and MCP-1 (CCL-2) in inflamed human corneas in vivo. Arch Ophthalmol 2003; 121: 825.
39. Yamagami S, Miyazaki D, Ono SJ, et al. Differential chemokine gene expression in corneal transplant rejection. Invest Ophthalmol Vis Sci 1999; 40: 2892.
40. Tanaka K, Yamagami S, Streilein JW. Evidence that T-helper type 2 cell-derived cytokines and eosinophils contribute to acute rejection of orthotopic corneal xenografts in mice. Transplantation 2005; 79: 1317.
41. Yamagami S, Hamrah P, Zhang Q, et al. Early ocular chemokine gene expression and leukocyte infiltration after high-risk corneal transplantation. Mol Vis 2005; 11: 632.
42. King WJ, Comer RM, Hudde T, et al. Cytokine and chemokine expression kinetics after corneal transplantation. Transplantation 2000; 70: 1225.
43. Torres PF, De Vos AF, van der Gaag R, et al. Cytokine mRNA expression during experimental corneal allograft rejection. Exp Eye Res 1996; 63: 453.
44. Qian Y, Hamrah P, Boisgerault F, et al. Mechanisms of immunothera-peutic intervention by anti-CD154 (CD40L) antibody in high-risk cor-neal transplantation. J Interferon Cytokine Res 2002; 22: 1217.
45. Ardjomand N, McAlister JC, Rogers NJ, et al. Modulation of costimu-lation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection. Invest Ophthalmol Vis Sci 2003; 44: 3899.
46. Qian Y, Boisgerault F, Benichou G, et al. Blockade of CD40-CD154 costimulatory pathway promotes survival of allogeneic corneal transplants. Invest Ophthalmol Vis Sci 2001; 42: 987.
47. Teo IA, Choi JW, Morlese J, et al. LightCycler qPCR optimisation for low copy number target DNA. J Immunol Methods 2002; 270: 119.
48. Pillai RG, Beutelspacher SC, Larkin DF, et al. Upregulation of chemo-kine expression in murine cornea due to mechanical trauma or endo-toxin. Br J Ophthalmol 2008; 92: 259.
49. He YG, Mellon J, Niederkorn JY. The effect of oral immunization on corneal allograft survival. Transplantation 1996; 61: 920.
50. Tsuchiya S, Yamabe M, Yamaguchi Y, et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26: 171.
51. Pearson LL, Castle BE, Kehry MR. CD40-mediated signaling in mono-cytic cells: Up-regulation of tumor necrosis factor receptor-associated factor mRNAs and activation of mitogen-activated protein kinase signaling pathways. Int Immunol 2001; 13: 273.
52. Hamrah P, Yamagami S, Liu Y, et al. Deletion of the chemokine receptor CCR1 prolongs corneal allograft survival. Invest Ophthalmol Vis Sci 2007; 48: 1228.
53. Bertelmann E, Ritter T, Vogt K, et al. Efficiency of cytokine gene transfer in corneal endothelial cells and organ-cultured corneas mediated by liposomal vehicles and recombinant adenovirus. Ophthalmic Res 2003; 35: 117.
54. Jessup CF, Brereton HM, Coster DJ, et al. In vitro adenovirus mediated gene transfer to the human cornea. Br J Ophthalmol 2005; 89: 658.
55. Arancibia-Carcamo CV, Oral HB, Haskard DO, et al. Lipoadenofection- mediated gene deliverytothe corneal endothelium: Prospects for modulating graft rejection. Transplantation 1998; 65: 62.
56. Tan PH, Beutelspacher SC, Wang YH, et al. Immunolipoplexes: An efficient, nonviral alternative for transfection of human dendritic cells with potential for clinical vaccination. Mol Ther 2005; 11: 790.
57. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997; 278: 290.
58. Tuppin P, Poinard C, Loty B, et al. Risk factors for corneal regraft in patients on the french waiting list. Cornea 2004; 23: 704.
59. Price MO, Thompson RW Jr, Price FW Jr. Risk factors for various causes of failure in initial corneal grafts. Arch Ophthalmol 2003; 121: 1087.